Daptomycin
Cyclic lipodepsipeptide antibiotic containing 13 amino acids and a decanoyl lipid tail from Streptomyces roseosporus — FDA-approved as Cubicin for complicated skin infections (2003) and S.
aureus bacteremia including right-sided endocarditis (2006), operating through calcium-dependent phosphatidylglycerol-specific membrane depolarization with rapid bactericidal activity against MRSA, VRE, and other multidrug-resistant Gram-positive pathogens
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
4 mg/kg – 12 mg/kg
Compound profile
Scientific & efficacy data
Immune
Peptide profile
Strong human trials
Daptomycin
4 mg/kg · Once daily
Molecular formula
C₇₂H₁₀₁N₁₇O₂₆
- Mol. weight
- 1,620.69 Da
- CAS number
- 103060-53-3
- PubChem
- 21585658
- Developed · 1980s (discovery by Eli Lilly); 2003 (FDA approval for cSSSI); 2006 (FDA approval for bacteremia/endocarditis)
- Cubist Pharmaceuticals
Cubist Pharmaceuticals (Merck)
Amino acid sequence
Decanoyl-LTPIKDVGRLLTGYVDGGQQVLTGSFighting Drug-Resistant Infections
Daptomycin is bactericidal against Gram-positive organisms including methicillin-resistant S. aureus, and the label's approved uses are specifically for susceptible isolates including methicillin-resistant ones [6]. Its mechanism is calcium-dependent binding to phosphatidylglycerol in the bacterial membrane; laboratory work suggests it discriminates between bacterial and human membranes partly because cholesterol weakens its binding [3].
Bloodstream Infections
Approved for S. aureus bloodstream infection in adults including right-sided infective endocarditis, at 6 mg/kg every 24 hours for 2 to 6 weeks [6]. The balancing facts belong in the same breath: it is explicitly NOT approved for left-sided endocarditis [6], and in complicated bacteraemia and endocarditis the standard 6 mg/kg dose succeeded significantly less often than higher doses (odds ratio 0.48 and 0.50 respectively) [5].
Skin Infection Treatment
Approved for complicated skin and skin-structure infections at 4 mg/kg every 24 hours for 7 to 14 days, in adults and in children from 1 to 17 years [6]. In the 18-child open-label study, 6 of 7 children with MRSA skin infection had a favourable clinical response at test of cure [4].
Dosing
How much do I take?
4 mg/kg – 12 mg/kg · once every 24 hours
4 mg/kg – 12 mg/kg
Once every 24 hours
Covers all 3 documented dose levels · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for treatment of mrsa bacteremia and right-sided infective endocarditis (fda-approved indication at 6 mg/kg) & complicated skin and skin structure infections including surgical site infections and diabetic foot infections (fda-approved at 4 mg/kg)
Best for
Treatment of MRSA bacteremia and right-sided infective endocarditis (FDA-approved indication at 6 mg/kg)
Daptomycin is particularly well-suited for individuals focused on treatment of mrsa bacteremia and right-sided infective endocarditis (fda-approved indication at 6 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complicated skin and skin structure infections including surgical site infections and diabetic foot infections (FDA-approved at 4 mg/kg)
Daptomycin is particularly well-suited for individuals focused on complicated skin and skin structure infections including surgical site infections and diabetic foot infections (fda-approved at 4 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
VRE bloodstream infections and endocarditis when ampicillin-based therapy is not feasible
Daptomycin is particularly well-suited for individuals focused on vre bloodstream infections and endocarditis when ampicillin-based therapy is not feasible. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Outpatient parenteral antibiotic therapy (OPAT) for Gram-positive infections requiring IV treatment
Daptomycin is particularly well-suited for individuals focused on outpatient parenteral antibiotic therapy (opat) for gram-positive infections requiring iv treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Daptomycin with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Intravenous infusion over 30 minutes (on the FDA label; 60 minutes for younger children) · Intravenous injection over 2 minutes (on the label for adults only — explicitly not for children)
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
The label's limitations of use are the sharpest safety facts here, because they describe failure rather than toxicity: daptomycin is not indicated for pneumonia, because pulmonary surfactant inactivates it directly [1][6], and not for left-sided infective endocarditis due to S.
aureus [6].
On toxicity, myopathy is defined on the label as muscle aching or weakness with CPK above ten times the upper limit of normal, and rhabdomyolysis with or without acute renal failure has been reported; CPK is to be monitored weekly, and more often in renal impairment or alongside a statin [6].
The largest statin comparison found myalgias in 3 of 49 (6.1%) on the combination against 5 of 171 (2.9%) on daptomycin alone (p=0.38), and CPK above 1,000 U/L in 5 of 49 (10.2%) against 9 of 171 (5.3%) (p=0.32) — numerically worse, not statistically so, and reversible on stopping [2].
The label also warns of anaphylaxis, eosinophilic pneumonia, DRESS, tubulointerstitial nephritis, peripheral neuropathy, Clostridioides difficile diarrhoea, and reduced efficacy in adults with moderate baseline renal impairment [6].
Higher doses cost more muscle enzyme elevation: CPK rises were significantly more frequent above 6 mg/kg than at standard dose [5].
Daptomycin has been approved since 2003 and the evidence base is genuinely large, but the specific numbers on this page come from named sources rather than from 'extensive clinical experience': the FDA label for indications, dosing and warnings [6], a 13-institution retrospective comparison for the statin interaction [2], and a systematic review and meta-analysis for the standard-versus-high-dose trade-off [5].
Paediatric evidence includes an 18-child open-label study with no control arm [4].
Two things the page previously implied but no source supports: that 8-12 mg/kg is a settled adult regimen — it is off-label in adults and the evidence for it is meta-analytic rather than from a dedicated trial [5] — and that a 4-6 week course is typical, which matches neither approved duration [6].
Common side effects · experienced by some users
CPK elevation
Asymptomatic creatine phosphokinase (CPK) elevation reported in 5.3-10.2% of patients, reflecting daptomycin's interaction with skeletal muscle phospholipid membranes. Usually mild (<5x ULN) and reversible.
Management: Monitor CPK weekly (baseline + weekly during therapy). If CPK >5x ULN with symptoms (myalgia, weakness), discontinue daptomycin. If CPK >10x ULN even without symptoms, strongly consider discontinuation. Temporarily discontinue statins during therapy.
GI effects (nausea, diarrhea, vomiting)
Nausea (5.8%), diarrhea (5.2%), vomiting (3.2%), and constipation are the most common non-skeletal adverse effects.
Management: Usually mild and self-limiting. Antiemetics for nausea if needed. Monitor for C. difficile infection if diarrhea is persistent or severe. Adequate hydration.
Headache and insomnia
Headache reported in 5.4% and insomnia in 4.5% of patients in clinical trials.
Management: Standard analgesics for headache. Sleep hygiene measures for insomnia. Usually resolve during treatment or after completion.
Injection site reactions
Pain, erythema, and mild phlebitis at the IV infusion site in 5.8% of patients.
Management: Rotate infusion sites. Use large-bore vein if available. 2-minute IV push may be better tolerated than 30-minute infusion for some patients.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Daptomycin
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Daptomycin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Beta-lactams (nafcillin, ceftaroline — 'seesaw effect' synergy: beta-lactam resistance in MRSA is associated with increased daptomycin susceptibility; ceftaroline + daptomycin combination therapy for persistent MRSA bacteremia) — May be used together under medical guidance.
- Safe:Rifampicin (synergistic biofilm penetration — rifampicin inhibits RNA synthesis in biofilm-embedded bacteria while daptomycin provides rapid bactericidal membrane activity) — May be used together under medical guidance.
- Safe:Trimethoprim-sulfamethoxazole (complementary mechanisms for VRE and complex Gram-positive infections; oral TMP-SMX enables step-down from IV daptomycin) — May be used together under medical guidance.
With medications
- Caution:Statins (HMG-CoA reductase inhibitors) — additive myotoxicity risk with daptomycin; consider temporary statin discontinuation during daptomycin therapy or monitor CPK more frequently — Use with caution—discuss with your healthcare provider.
- Caution:Tobramycin (in vitro antagonism demonstrated when co-administered with daptomycin for certain organisms — potential reduced efficacy) — Use with caution—discuss with your healthcare provider.
- Caution:Use for pneumonia or respiratory infections — daptomycin is inactivated by pulmonary surfactant; this is an absolute clinical restriction, not a drug interaction — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Daptomycin. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Strong human trials · first signs hours 0-48 (initiation)
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
FDA approved for complicated skin and skin-structure infections (adults and children 1-17) and for Staphylococcus aureus bloodstream infection (adults including right-sided endocarditis, and children 1-17)
NOT indicated for pneumonia, NOT for left-sided endocarditis, NOT recommended under 1 year of age.
Onset of effects
Rapid
(hours to days)
How it works
Daptomycin is a lipopeptide antibiotic that kills dangerous bacteria like MRSA by disrupting their cell membranes, making it crucial for treating serious skin, heart, and bloodstream infections.
The deeper mechanism
Daptomycin is a 13-amino acid cyclic lipopeptide containing an unusual β-methyl group at the N-terminus and an N-decanoyl fatty acid modification that anchors the peptide into bacterial cell membranes.
Upon calcium-dependent conformational changes and oligomerization on the membrane surface, daptomycin forms membrane-disrupting pores through an α-helical intermediate state, causing rapid depolarization of the bacterial membrane potential, efflux of potassium ions, and loss of cellular contents leading to bactericidal activity.
Its mechanism is unique among antibiotics and provides activity against Gram-positive bacteria including vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA).
What to expect
Hours 0-48 (initiation)
What you might notice
- IV infusion generally well-tolerated; mild injection site discomfort possible
- Bactericidal activity begins within hours of achieving therapeutic levels
- Baseline CPK obtained for monitoring
- Nausea or headache may occur with first doses
What's normal
- Daptomycin achieves peak bactericidal activity within the first 24 hours
- For bacteremia, blood cultures should be repeated at 48-72 hours to assess clearance
- Once-daily dosing is established from the start — no loading dose needed
- Mild GI effects are common initially and usually transient
What's next
- Continue daily IV dosing per indicated schedule
- Repeat blood cultures at 48-72 hours for bacteremia
- First CPK check at day 3-7
- Assess clinical response (fever, WBC, hemodynamics) at 48-72 hours
Days 3-14 (active treatment)
What you might notice
- Clinical improvement: defervescence, resolving signs of infection
- Blood culture clearance expected by day 3-5 for susceptible organisms
- CPK may show mild elevation — usually asymptomatic
- For cSSSI: visible improvement in skin infection by day 3-4
What's normal
- cSSSI treatment typically completed in 7-14 days
- Bacteremia clearance should occur by day 3-5; if persistent, reassess
- Mild CPK elevation is common and not necessarily an indication to stop
- Once-daily dosing may allow OPAT transition for clinically stable patients
What's next
- Continue weekly CPK monitoring throughout treatment
- For cSSSI: complete 7-14 day course as clinically indicated
- For bacteremia: continue until 2 weeks after first negative blood culture
- For endocarditis: plan for 4-6 week total treatment course
Week 2-6 (extended treatment/completion)
What you might notice
- Infection resolving or resolved depending on indication
- Endocarditis patients: continued improvement on echocardiographic follow-up
- CPK typically returns to normal within 1 week of completing therapy
- Overall recovery and return to baseline function
What's normal
- Extended courses (4-6 weeks) are standard for endocarditis and osteoarticular infections
- OPAT allows patients to receive remaining treatment at home
- CPK should be monitored weekly through end of therapy
- Post-treatment relapse surveillance is recommended for endocarditis
What's next
- Complete the full treatment course per infectious disease guidance
- Final CPK check at end of treatment to confirm normalization
- Resume statins if held during daptomycin therapy (after 1 week off daptomycin)
- Follow-up blood cultures and clinical assessment post-treatment
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Daptomycin over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Clinical trials
Tested in people
113 registered studies, 7 still enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 22,640 people took part in the studies that actually administered Daptomycin. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
22-CONS-01
Centre Hospitalier Universitaire De Nice
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
Intermountain Health Care, Inc.
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
West Virginia University
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Daptomycin is named as an intervention; studies that only mention it in passing are not.
Questions
Frequently asked
Why can't daptomycin be used for pneumonia?
Daptomycin is completely inactivated by pulmonary surfactant — the phospholipid-rich substance that lines the alveoli in the lungs. Surfactant phosphatidylcholine binds daptomycin's lipid tail and sequesters the drug, preventing it from interacting with bacterial membranes. A clinical trial comparing daptomycin to ceftriaxone for community-acquired pneumonia (CAP) showed daptomycin was significantly inferior, confirming that it should never be used for any lung infection. This is the single most important clinical limitation to remember.
How was daptomycin 'rescued' from failure?
Eli Lilly discovered daptomycin in the 1980s from Streptomyces roseosporus but abandoned it due to skeletal muscle toxicity at the twice-daily dosing used in initial trials. Cubist Pharmaceuticals acquired the rights and made the crucial discovery that once-daily dosing maintained the same antimicrobial efficacy while dramatically reducing myotoxicity. The 24-hour drug-free interval between daily doses allows skeletal muscle cells to recover from daptomycin's phospholipid membrane effects. This pharmacological insight transformed daptomycin from a failed drug candidate into one of the most important antibiotics of the 21st century.
What is the 'seesaw effect' with ceftaroline?
The seesaw effect describes an inverse relationship between daptomycin and beta-lactam resistance in S. aureus: mutations that increase daptomycin MIC (such as changes in membrane phospholipid composition) simultaneously increase susceptibility to beta-lactams. This means adding a beta-lactam like ceftaroline to daptomycin therapy can restore or enhance activity against daptomycin-resistant or daptomycin-nonsusceptible MRSA. The daptomycin + ceftaroline combination has become a standard salvage regimen for persistent MRSA bacteremia.
Why is CPK monitoring required?
Daptomycin interacts with skeletal muscle cell membranes (which contain phosphatidylglycerol-like phospholipids) similarly to how it disrupts bacterial membranes, though at a much lower degree at therapeutic concentrations. This can cause skeletal muscle fiber damage, releasing creatine phosphokinase (CPK) into the blood. CPK monitoring weekly allows early detection of myotoxicity before it progresses to symptomatic myopathy or rhabdomyolysis. CPK >5x ULN with muscle symptoms or >10x ULN without symptoms is the typical threshold for discontinuation.
How does daptomycin compare to vancomycin for MRSA?
Both are first-line options for serious MRSA infections, but they have important differences. Daptomycin offers several advantages: faster bactericidal killing, once-daily dosing (vs vancomycin's twice-daily with trough monitoring), no need for therapeutic drug monitoring in most patients, and activity against vancomycin-intermediate (VISA) and some vancomycin-resistant strains. Vancomycin's advantages include broader evidence base, IV-to-oral step-down option, ability to treat pneumonia, and no restriction against lung infections. For MRSA bacteremia specifically, several comparative studies suggest daptomycin may achieve faster bloodstream clearance.
Is daptomycin effective against biofilms?
Yes, daptomycin maintains bactericidal activity against biofilm-embedded and stationary-phase bacteria, unlike many conventional antibiotics that require actively growing cells. This makes daptomycin particularly valuable for prosthetic joint infections, intravascular device infections, and endocarditis vegetations where biofilm-tolerant bacterial subpopulations survive standard antibiotic therapy. Combination with rifampicin further enhances anti-biofilm activity, as rifampicin penetrates the biofilm matrix while daptomycin provides the membrane-targeting kill.
Further reading
History & related research
History · since 1987
The antibiotic Eli Lilly threw away—rescued by one determined doctor.
Daptomycin is an antibiotic that kills superbugs like MRSA and VRE by punching holes in their cell walls. It was discovered in 1987 but abandoned by Eli Lilly due to toxicity.
Read the full history of DaptomycinReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Daptomycin, on one page.